MCID: VRL010
MIFTS: 52

Viral Hepatitis

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 54 3 15 71 32
Hepatitis, Viral, Animal 43 71
Animal Viral Hepatitis 12 17
Viral Hepatitis with Hepatic Coma 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 43 D006524
UMLS 71 C0019194 C0042721

Summaries for Viral Hepatitis

CDC : 3 Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to hepatitis a and hepatitis d. An important gene associated with Viral Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and PI3K-Akt signaling pathway. The drugs Atorvastatin and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are Reduced mammosphere formation and liver/biliary system

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

Wikipedia : 74 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 34.0 SEPSECS IFNA2 IFNA1 GPT GGT1 F2
2 hepatitis d 33.7 IFNA2 IFNA1 GPT F2
3 non-a-e hepatitis 33.6 F2 ALB
4 acute liver failure 33.3 SLC17A5 GPT FGL2 F2 ALB
5 hepatitis e 33.1 MIR122 GPT GGT1 F2 ALB
6 hepatitis c 32.8 MX1 MIR122 KRT18 IFNA2 IFNA1 HFE
7 hepatitis b 32.5 TLR2 SLC17A5 MX1 IFNA2 IFNA1 GPT
8 hepatitis 31.9 SLC17A5 SEPSECS KRT18 IL18BP IFNA2 IFNA1
9 hepatic coma 31.9 GPT F2 ALB AFP
10 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.6 IFNA2 HFE ALB
11 splenomegaly 31.5 IFNA2 IFNA1 FAS
12 obstructive jaundice 31.4 SLC17A5 GPT GGT1 F2 ALB
13 hepatic encephalopathy 31.4 SLC17A5 GPT F2 ALB AFP
14 cryoglobulinemia 31.4 IFNA2 IFNA1 GPT
15 cholestasis 31.4 SLC17A5 SERPINA1 GPT GGT1 F2 ALB
16 acute kidney failure 31.3 GPT F2 ALB
17 fatty liver disease, nonalcoholic 1 31.3 SLC17A5 GPT GGT1
18 syphilis 31.3 GPT FAS F2 ALB
19 exanthem 31.2 IFNA1 GPT F2 ALB
20 portal hypertension 31.2 GPT F2 ALB
21 cryoglobulinemia, familial mixed 31.2 IFNA2 IFNA1
22 aplastic anemia 31.2 IFNA1 HFE FASLG FAS ALB
23 bilirubin metabolic disorder 31.2 SLC17A5 GPT GGT1 F2 ALB AFP
24 schistosomiasis 31.2 GPT GGT1 F2 ALB
25 opisthorchiasis 31.2 GPT GGT1 AFP
26 typhoid fever 31.2 GPT GGT1 F2 ALB
27 cholecystitis 31.1 KRT18 GPT F2 ALB
28 alcohol use disorder 31.1 SLC17A5 HFE GPT GGT1 ALB ABCB7
29 hepatorenal syndrome 31.1 GPT F2 ALB AFP
30 immune deficiency disease 31.1 TLR2 IFNA1 GPT FASLG FAS
31 cholelithiasis 31.1 SERPINA1 GPT GGT1 ALB
32 hypothyroidism 31.0 IFNA2 IFNA1 GPT F2 ALB
33 portal vein thrombosis 31.0 IFNA2 IFNA1 F2 AFP
34 acalculous cholecystitis 31.0 GPT F2 ALB
35 hypersplenism 30.9 GPT F2 ALB
36 cholangitis 30.9 SLC17A5 GPT GGT1 F2 ALB
37 siderosis 30.9 SERPINA1 HFE GPT
38 dysentery 30.9 TLR2 IFNA2 GPT ALB
39 neutropenia 30.9 IFNA2 IFNA1 GPT FASLG ALB
40 fatty liver disease 30.8 SLC17A5 MIR122 KRT18 HFE GPT GGT1
41 human immunodeficiency virus infectious disease 30.7 MX1 IFNA1 FASLG FAS
42 hemochromatosis, type 1 30.7 SERPINA1 SEPSECS HFE GPT ABCB7
43 thrombocytopenia 30.7 TLR2 IFNA2 IFNA1 GPT GGT1 FASLG
44 sclerosing cholangitis 30.7 GPT GGT1 F2 ALB
45 liver cirrhosis 30.7 TLR2 SLC17A5 SERPINA1 MIR122 KRT18 IFNA1
46 alcoholic liver cirrhosis 30.7 TLR2 SLC17A5 GPT F2 ALB AFP
47 autoimmune hepatitis 30.7 SLC17A5 SEPSECS KRT18 IFNA1 GPT GGT1
48 substance abuse 30.7 GPT ALB ABCB7
49 diabetes mellitus 30.6 TLR2 SERPINA1 HFE GPT GGT1 FASLG
50 endocarditis 30.6 TLR2 F2 ALB

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.61 ABCB7 AFP ALB FAS FASLG HFE
2 mortality/aging MP:0010768 9.44 ABCB7 AFP ALB F2 FAS FASLG

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 274)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
3
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
6
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
7
Halofantrine Approved Phase 4 69756-53-2 37393
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
9
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Lopinavir Approved Phase 4 192725-17-0 92727
12
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
13
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
14
Lactulose Approved Phase 4 4618-18-2 11333
15
Methadone Approved Phase 4 76-99-3 4095
16
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
17
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
18
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
19
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
20
Cobicistat Approved Phase 4 1004316-88-4
21
Ribavirin Approved Phase 4 36791-04-5 37542
22
Nevirapine Approved Phase 4 129618-40-2 4463
23
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
24
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
27
Adefovir Investigational Phase 4 106941-25-7
28
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
29 Anticholesteremic Agents Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Interferon alpha-2 Phase 4
32 interferons Phase 4
33 Interferon-alpha Phase 4
34 Vitamins Phase 4
35 Immunologic Factors Phase 4
36 Trace Elements Phase 4
37 Nutrients Phase 4
38 Micronutrients Phase 4
39 Calciferol Phase 4
40 Immunosuppressive Agents Phase 4
41 Hypoglycemic Agents Phase 4
42 Dihydroxycholecalciferols Phase 4
43 Calcium, Dietary Phase 4
44 Dextrans Phase 4
45 Anticoagulants Phase 4
46 Plasma Substitutes Phase 4
47 Iron-Dextran Complex Phase 4
48 Blood Substitutes Phase 4
49 Calcineurin Inhibitors Phase 4
50 Lamivudine, zidovudine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 312)
# Name Status NCT ID Phase Drugs
1 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
2 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
4 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
5 A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus Completed NCT01327547 Phase 4 Maraviroc;Placebo
6 Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro) Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
7 Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
8 Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL Completed NCT02039362 Phase 4 Tenofovir DF
9 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
10 Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
11 A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
12 A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
13 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
14 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
15 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
16 Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China Completed NCT01340950 Phase 4 zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz
17 A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. Completed NCT00866021 Phase 4 Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs
18 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
19 Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects Completed NCT00125775 Phase 4
20 Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study) Completed NCT03499639 Phase 4 Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
21 Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
22 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
23 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
24 Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants Completed NCT04237246 Phase 4 Tacrolimus
25 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
26 Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial Recruiting NCT03933384 Phase 4 Tenofovir alafenamide;Entecavir
27 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
28 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Recruiting NCT02973295 Phase 4 Silymarin
29 Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy Recruiting NCT04201808 Phase 4 Tenofovir Alafenamide 25 MG
30 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection: an Open-label Randomized Clinical Trial Recruiting NCT03854630 Phase 4 Engerix-B
31 Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) Recruiting NCT04436601 Phase 4 Polyethylene Glycols;Lactulose
32 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Recruiting NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
33 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
34 Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam Active, not recruiting NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
35 Expression of Inflammasomes in HCV Patients Before and After Treatment Not yet recruiting NCT04244383 Phase 4
36 RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
37 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
38 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
39 Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24 Unknown status NCT00336518 Phase 3 peginterferon alfa-2a;ribavirin
40 Growth Hormone Therapy and Its Effect on Nitrogen Metabolism and Malnutrition in Liver Cirrhosis Unknown status NCT03420144 Phase 2, Phase 3 Standard Medical Therapy;Growth Hormone
41 Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) Unknown status NCT01135056 Phase 3 Sorafenib tosylate
42 Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma Unknown status NCT02568748 Phase 3
43 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
44 RECURRENCE RATE OF HEPATOCELLULAR CARCINOMA AFTER TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH DIRECT ACTING ANTIVIRALS: RANDOMIZED CONTROLLED PHASE 3 TRIAL (CAUTIOUS TRIAL) Unknown status NCT03551444 Phase 3 Administration of DAA-based treatment
45 Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy Unknown status NCT02215525 Phase 3
46 Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life Completed NCT01008293 Phase 2, Phase 3 VSL#3;Lactulose
47 Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
48 Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy Completed NCT02060058 Phase 3 Stop trial intervention for boceprevir, PEG-IFN and RBV
49 A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
50 A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment Completed NCT01595685 Phase 3 Telbivudine;Entecavir

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

40
Liver, Testes, T Cells, Kidney, Bone, Thyroid, Bone Marrow

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 18182)
# Title Authors PMID Year
1
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 61 54
20155784 2010
2
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
3
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 54 61
19769633 2009
4
Bicyclol: a novel drug for treating chronic viral hepatitis B and C. 54 61
19149648 2009
5
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. 61 54
19252365 2009
6
Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. 54 61
19103527 2008
7
Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. 61 54
18801734 2008
8
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. 61 54
18422961 2008
9
Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. 54 61
19034238 2008
10
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. 54 61
18671818 2008
11
Significant correlation between surgical stress of hepatectomy and changes in the serum levels of HGF, IL-6 and soluble Fas in patients with viral hepatitis. 61 54
18795698 2008
12
Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. 61 54
18498412 2008
13
Natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatitis. 61 54
18469546 2008
14
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. 54 61
18307594 2008
15
The role of interleukin-22 in hepatitis C virus infection. 61 54
18191408 2008
16
Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. 61 54
18167134 2008
17
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. 61 54
17919273 2008
18
Hyperferritinemia in the Chinese and Asian community: a retrospective review of the University of British Columbia experience. 54 61
18209779 2008
19
Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha. 54 61
18019713 2007
20
HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. 61 54
17573946 2007
21
[A close relationship between viral hepatitis B and Toll-like receptor 2]. 61 54
17669234 2007
22
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 54 61
17498256 2007
23
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. 54 61
17589934 2007
24
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. 54 61
17439526 2007
25
Modafinil's use in combating interferon-induced fatigue. 54 61
17318387 2007
26
[Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma]. 61 54
17515071 2007
27
Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. 61 54
17148690 2007
28
[Some aspects of human mineral metabolic disturbances in viral hepatitis of various genesis]. 54 61
17436703 2007
29
Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. 54 61
17274827 2007
30
Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. 61 54
17328497 2007
31
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. 61 54
17192324 2007
32
[Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma]. 54 61
17941466 2007
33
[Utility of analytical parameters in the diagnosis of liver disease]. 54 61
17373869 2007
34
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. 61 54
17075991 2006
35
Molecular detection of transfusion transmitted virus coinfection with some hepatotropic viruses. 54 61
17076531 2006
36
An official ATS statement: hepatotoxicity of antituberculosis therapy. 54 61
17021358 2006
37
Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. 54 61
16858074 2006
38
Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. 54 61
16776568 2006
39
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. 54 61
16702862 2006
40
Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. 61 54
16530290 2006
41
Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. 61 54
16448453 2006
42
Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. 61 54
16498048 2006
43
Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. 54 61
16429839 2006
44
A novel panel of blood markers to assess the degree of liver fibrosis. 54 61
16317693 2005
45
[Progress of the study on the relationship between MxA and interferon therapy of viral hepatitis]. 61 54
16381656 2005
46
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. 54 61
16437596 2005
47
Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. 54 61
16227290 2005
48
[Alanine aminotransferase is a substitute marker of viral hepatitis]. 61 54
16408624 2005
49
Iron in nonhemochromatotic liver disorders. 54 61
16315139 2005
50
Typhoid fever and viral hepatitis in a G6PD deficient individual. 54 61
16599045 2005

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 SERPINA1 IL18BP IFNA2 IFNA1 FGL2 FASLG
2 extracellular exosome GO:0070062 9.7 SERPINA1 MIR122 KRT18 IL18BP GPT GGT1
3 extracellular space GO:0005615 9.44 SERPINA1 MIR122 IL18BP IFNA2 IFNA1 HFE

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.71 SERPINA1 F2 ALB AFP
2 blood coagulation GO:0007596 9.56 SERPINA1 IFNA2 IFNA1 F2
3 type I interferon signaling pathway GO:0060337 9.54 MX1 IFNA2 IFNA1
4 response to lipopolysaccharide GO:0032496 9.46 TLR2 IL18BP GGT1 FASLG
5 necroptotic signaling pathway GO:0097527 9.32 FASLG FAS
6 extrinsic apoptotic signaling pathway GO:0097191 9.13 KRT18 FASLG FAS
7 acute-phase response GO:0006953 8.8 SERPINA1 HFE F2

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....